Figure 5.

Therapeutic efficacy of N9 mAbs against a lethal H7N9 virus challenge in mice. BALB/c mice (n = 5 per group) were infected i.n. with 5 × LD₅₀ of H7N9 SH/2/13 virus, followed by injection i.p. with indicated doses of each mAb 24 h later. An isotype-matched and irrelevant mAb was used as a negative control. (A-C) Survival (upper panel) and weight loss (lower panel) (n = 5 per group) were monitored for up to 20 days. (*, p < 0.05, 5F2 (10 mg/kg at 8, 10, 12d; 30 mg/kg at 10, 12d; 50 mg/kg at 6, 8, 10, 12d), 2H10 (30 mg/kg at 10, 12d; 50 mg/kg at 10, 12d), 7D8 (30 mg/kg at 10, 12d; 50 mg/kg at 6, 8, 10, 12d), 7H2 (30 mg/kg at 8, 10, 12d; 50 mg/kg at 6, 8, 10, 12d), D3 (10 mg/kg at 6, 8, 10, 12d; 30 mg/kg at 6, 8, 10, 12d; 50 mg/kg at 6, 8, 10, 12d), F6 (30 mg/kg at 10, 12d; 50 mg/kg at 10, 12d), B7C2 (30 mg/kg at 10, 12d; 50 mg/kg at 10, 12d) compared to the negative control by student t-test). (D) Lungs were collected on the 3, 5, and 7 d after infecting virus and viral titres were determined by titrating in MDCK cells. Titres were expressed as log10PFU/ml (n = 3); SD was shown with an error bar. Significant differences between titres measured in each group and control groups were shown as *, p < 0.05.